Compare Royal Caribbean Cruises Ltd (RCL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Smith & Nephew plc — how do they compare? Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 6.8× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Smith & Nephew plc for 121 Days on average.
| RCL | SNN | |
|---|---|---|
Market Cap | $75.26B | $11.10B |
Volume | 1,958,628 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $37.17 |
52-Week Low | $230.30 | $26.42 |
Typical Hold Time | 85 Days | 121 Days |
Enterprise Value | $97.91B | $14.13B |
Dividend Yield | 2.13% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.39, down 0.35% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamental performance with 2025 revenue of $17.93B and net income of $4.27B, representing a 23.54% margin. Recent Q2 2026 earnings beat expectations at $4.21 EPS versus $3.98 expected, while the company expands into resorts through a $3B Sandals stake acquisition announced September 2026.
RCL presents a compelling growth story with improving profitability and strategic expansion, though elevated valuation multiples and high debt levels warrant caution. Analyst consensus remains bullish with a $346.67 price target representing 23% upside potential, but investors should monitor execution risks from the Sandals integration and sensitivity to fuel costs projected at $1.34B for 2026.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
